Hydra Biosciences and Boehringer Ingelheim announce worldwide collaboration to develop small-molecule inhibitors for the treatment of central nervous system diseases and disorders

Hydra Biosciences, Inc., a leader in the field of Transient Receptor Potential (TRP) channel modulation, and Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, jointly announced today that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders.

“We are extremely pleased to be working with Boehringer Ingelheim, a company that shares our dedication for developing innovative products that improve patient’s lives. The combination of Hydra’s unique understanding of TRP channels and BI’s proven research, development and commercialization capabilities provides an excellent opportunity to maximize the potential of these novel targets,” said Russell Herndon, President and CEO of Hydra Biosciences.

“We are very excited to collaborate with Hydra Biosciences and to be able to build on their significant expertise in the field of TRP channels in our endeavors to provide the numerous patients suffering from CNS disorders with new treatments that offer meaningful therapeutic improvement”, said Bernd Sommer, VP of Neuroscience Research at Boehringer Ingelheim.

Under the terms of the collaboration agreement, the companies will work together to identify and advance candidate inhibitors. Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration. Hydra will receive an upfront payment, additional research funding, and is eligible to receive milestone payments and tiered royalty payments on future product sales.